Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARAY Stock Forecast 2026-2027
$0.84
Current Price
$95.21M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ARAY Price Targets
+376.2%
To High Target of $4.00
+361.3%
To Median Target of $3.88
+346.4%
To Low Target of $3.75
ARAY Price Momentum
-3.4%
1 Week Change
-7.7%
1 Month Change
-62.5%
1 Year Change
+2.4%
Year-to-Date Change
-71.5%
From 52W High of $2.95
+7.7%
From 52W Low of $0.78
📊 TOP ANALYST CALLS
Did ARAY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Accuray is one of their latest high-conviction picks.
Latest ARAY Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ARAY has a bullish consensus with a median price target of $3.88 (ranging from $3.75 to $4.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.84, the median forecast implies a 361.3% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Marie Thibault at BTIG, projecting a 376.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARAY Analyst Ratings
2
Buy
0
Hold
0
Sell
ARAY Price Target Range
Low
$3.75
Average
$3.88
High
$4.00
Current: $0.84
Latest ARAY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARAY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 6, 2025 | BTIG | Marie Thibault | Buy | Maintains | $4.00 |
| Aug 14, 2025 | BTIG | Maria Thibault | Buy | Maintains | $5.00 |
| Feb 13, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $9.00 |
| Oct 4, 2023 | B. Riley Securities | Neil Chatterji | Buy | Reiterates | $7.50 |
| Aug 31, 2022 | B. Riley Securities | Buy | Initiates | $N/A | |
| Jun 24, 2022 | BTIG | Marie Thibault | Buy | Maintains | $7.00 |
| Jun 23, 2022 | B. Riley Securities | Kara Anderson | Buy | Initiates | $7.50 |
| Dec 22, 2021 | Loop Capital | Buy | Initiates | $N/A | |
| Jan 21, 2020 | BTIG Research | Buy | Upgrade | $N/A | |
| Jan 21, 2020 | BTIG | Buy | Upgrade | $N/A | |
| Nov 1, 2018 | Citigroup | Amit Hazan | Neutral | Upgrade | $3.90 |
| Aug 17, 2018 | Citigroup | Sell | Maintains | $3.50 | |
| Dec 19, 2017 | JP Morgan | Underweight | Downgrade | $N/A | |
| Dec 13, 2017 | JP Morgan | Underweight | Downgrade | $N/A | |
| Nov 30, 2017 | Lake Street | Buy | Initiates | $N/A | |
| Aug 23, 2017 | Jefferies | Buy | Maintains | $6.00 | |
| Feb 6, 2017 | Aegis Capital | Buy | Initiates | $N/A | |
| Dec 14, 2016 | JP Morgan | Neutral | Downgrade | $N/A | |
| Sep 13, 2016 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Dec 22, 2015 | RBC Capital | Sector Perform | Initiates | $N/A |
Accuray Incorporated (ARAY) Competitors
The following stocks are similar to Accuray based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Accuray Incorporated (ARAY) Financial Data
Accuray Incorporated has a market capitalization of $95.21M with a P/E ratio of -42.0x. The company generates $450.90M in trailing twelve-month revenue with a -4.3% profit margin.
Revenue growth is +16.8% quarter-over-quarter, while maintaining an operating margin of +3.7% and return on equity of -36.1%.
Valuation Metrics
Market Cap
$95.21M
Enterprise Value
$178.35M
P/E Ratio
-42.0x
PEG Ratio
-0.1x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
+16.8%
Gross Margin
+28.3%
Operating Margin
+3.7%
Net Margin
-4.3%
EPS Growth
-7.5%
Financial Health
Cash/Price Ratio
+122.3%
Current Ratio
1.6x
Debt/Equity
289.7x
ROE
-36.1%
ROA
+0.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Accuray Incorporated (ARAY) Business Model
About Accuray Incorporated
What They Do
Develops precise tumor treatment medical devices.
Business Model
Accuray generates revenue by designing, manufacturing, and selling advanced radiation therapy systems like the CyberKnife and TomoTherapy systems. These products are used in hospitals and clinics globally, enabling precise cancer treatments that improve patient outcomes and enhance the effectiveness of radiation therapy.
Additional Information
The company is well-positioned in the oncology sector and focuses on integrating cutting-edge technology with patient-centered care. Its commitment to innovation and improving the quality of life for cancer patients underlines its potential for growth in the evolving healthcare market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
990
CEO
Mr. Stephen R. LaNeve MBA
Country
United States
IPO Year
2007
Website
www.accuray.comAccuray Incorporated (ARAY) Latest News & Analysis
Latest News
Radiation Therapy-Focused Accuray Details Workforce Reduction, Outsourcing In Major Transformation Push
1 month ago
Quick Summary
Accuray Incorporated (NASDAQ: ARAY) is initiating a strategic transformation to improve cost controls and accountability, aiming for enhanced profitability post-implementation.
Why It Matters
Accuray's transformation plan aims to enhance profitability through cost controls and improved execution, signaling potential for better financial performance and increased shareholder value.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
The company will implement a plan involving organizational realignment and cost structure adjustments, affecting about 15% of employees to enhance competitiveness and support long-term strategy.
Why It Matters
The plan indicates cost-cutting measures and workforce reduction, signaling potential short-term disruptions but aiming for long-term profitability and competitiveness, impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Accuray Incorporated (ARAY) will hold its Q1 2026 earnings call on November 5, 2025, at 4:30 PM EST, featuring CEO Stephen LaNeve and CFO Ali Pervaiz.
Why It Matters
Accuray's Q1 earnings call provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment in the medical technology sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Accuray Incorporated (NASDAQ: ARAY) announced its financial results for Q1 ending September 30, 2025, on November 5, 2025. Further details on performance were not provided in the excerpt.
Why It Matters
Accuray's Q1 financial results may indicate its performance trends, impacting stock valuation and investor sentiment. Key metrics will influence investment decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Accuray's latest quarter showed revenue and order declines, worsening gross margins, and a sixth straight decline in backlog. A new CEO and transformation plan present potential, but operational improvements are uncertain.
Why It Matters
Accuray's weak financial performance and declining backlog signal challenges ahead, raising concerns about its competitive position and future profitability under new leadership.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Accuray Incorporated has granted equity inducement awards to its new CEO, Stephen La Neve, in compliance with NASDAQ Listing Rules.
Why It Matters
Accuray's equity inducement awards for its new CEO signal management confidence and potential strategic shifts, impacting future performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ARAY Stock
What is Accuray Incorporated's (ARAY) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Accuray Incorporated (ARAY) has a median price target of $3.88. The highest price target is $4.00 and the lowest is $3.75.
Is ARAY stock a good investment in 2026?
According to current analyst ratings, ARAY has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARAY stock?
Wall Street analysts predict ARAY stock could reach $3.88 in the next 12 months. This represents a 361.3% increase from the current price of $0.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Accuray Incorporated's business model?
Accuray generates revenue by designing, manufacturing, and selling advanced radiation therapy systems like the CyberKnife and TomoTherapy systems. These products are used in hospitals and clinics globally, enabling precise cancer treatments that improve patient outcomes and enhance the effectiveness of radiation therapy.
What is the highest forecasted price for ARAY Accuray Incorporated?
The highest price target for ARAY is $4.00 from Marie Thibault at BTIG, which represents a 376.2% increase from the current price of $0.84.
What is the lowest forecasted price for ARAY Accuray Incorporated?
The lowest price target for ARAY is $3.75 from at , which represents a 346.4% increase from the current price of $0.84.
What is the overall ARAY consensus from analysts for Accuray Incorporated?
The overall analyst consensus for ARAY is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.88.
How accurate are ARAY stock price projections?
Stock price projections, including those for Accuray Incorporated, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 2:10 AM UTC